Remoxipide is one of the substituted benzamides and a competitive antagonist at D2 receptors in tissue of animals as well as human brain. Remoxipride exhibits simple. Uncomplicated pharmacokinetics. lts plasma concentration. after various routes
of
administration, decays with a monoexponential decline. High bioavailability. No first-pass effect, and only a 4-fold variability in AUC are some of its main pharmacokinetic properties.
The clinical expectation for remoxipride, based on the drug's pharmacological profile, have been realized in many open and controlled trials. Remoxipride combines the advantages of good antipsychotic efficacy for both positive and negative
symptoms
in
schizophrenia. Low incidence of extrapyramidal symptoms, reduced need for anticholinergic medication, low incidence of drowsiness/somnolence and little influence on cardiovascular functions, haematology and clinical laboratory investigation.
Remoxipride
has been shown to exert a relapse-preventing effect. Too.
|